

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A method for the treatment of arthritis in a subject, said method comprising administering to the subject an effective amount of an agent selected from the group consisting of
 - (a) an antibody to granulocyte-colony stimulating factor (G-CSF);
 - (b) an antibody to granulocyte-colony stimulating factor receptor (G-CSFR); and
 - (c) a soluble G-CSFR, and a G-CSF-binding fragment of said G-CSFR,
 wherein the agent inhibits the activity or level of expression of G-CSF or G-CSFR.
2. (Original) The method of Claim 1 wherein the arthritis is chronic inflammatory arthritis.
3. (Original) The method of Claim 1 wherein the condition is rheumatoid arthritis (RA).
4. (Previously Presented) The method of Claim 1 wherein the arthritis is collagen-induced arthritis (CIA).
5. (Previously Presented) The method of Claim 1 wherein the subject is a mammal.
- 6.-7. (Cancelled)
8. (Previously presented) The method of Claim 5 wherein the mammal is a human.
- 9.-11. (Cancelled)
12. (Previously Presented) The method of Claim 1 wherein the antibody is a monoclonal antibody.
13. (Previously Presented) The method of Claim 1 wherein the antibody is a polyclonal

antibody.

14.-21. (Cancelled)

22. (Withdrawn) A composition for treating arthritis comprising an antagonist which inhibits the activity or level of expression of G-CSF or G-CSFR, together with a pharmaceutically acceptable carrier or diluent.

23.-28. (Cancelled)

29. (Withdrawn) The composition of Claim 22 wherein the antagonist is an antibody to G-CSF or G-CSFR.

30. (Withdrawn) The composition of Claim 29 wherein the antibody is a monoclonal antibody.

31. (Withdrawn) The composition of Claim 29 wherein the antibody is a polyclonal antibody.

32. (Withdrawn) The composition of Claim 22 wherein the antagonist is soluble G-CSFR or a G-CSF-binding fragment thereof.

33.-35. (Cancelled)

36. (Withdrawn) The composition of Claim 22 wherein the antagonist is DNA or RNA and comprises a sense or antisense polynucleotide sequence or a genetic sequence encoding G-CSF or G-CSFR.

37.-45. (Cancelled)

46. (New) A method for the treatment of arthritis in a subject, said method consisting essentially of administering to the subject, an effective amount of an agent selected from the group consisting of:

- (a) an antibody to granulocyte-colony stimulating factor (G-CSF);
- (b) an antibody to granulocyte-colony stimulating factor receptor (G-CSFR);

and

(c) a soluble G-CSFR, and a G-CSF-binding fragment of said G-CSFR,
wherein the agent inhibits the activity or level of expression of G-CSF or G-
CSFR.